Pakistan third most polluted country
Pakistan was ranked the third most polluted country in the world in 2024 while Chad topped the list, according to the annual World Air Quality Report published by Swiss air technology company IQAir on Tuesday.
According to the report, Chad remained the most polluted country overall, followed by Bangladesh, Pakistan, the Democratic Republic of Congo and India.
Pakistan's average concentration of PM2.5 particles – those less than 2.5 microns in diameter — was 73.7 micrograms per cubic metre (?g/m³), nearly 15 times the safe levels set by the World Health Organisation (WHO).
However, despite the record-breaking smog, Pakistan's overall air pollution levels remained unchanged from 2023.
In the Central and South Asia region, Pakistan ranked second, just behind Bangladesh, with Lahore, Multan, Peshawar and Sialkot among the 15 most polluted cities in the region.
The report pointed out that Pakistan faces persistently high levels of pollution from multiple sources, including biomass burning, industrial activities, vehicular emissions, brick kilns and construction dust.
Compared to 2023, Peshawar, Islamabad, Rawalpindi and Lahore saw a rise in their annual average pollution levels, while Faisalabad's increase was negligible.
On the other hand, Karachi's PM2.5 readings declined, dropping from over 55 micrograms per cubic metre in 2023 to around 46 micrograms per cubic metre in 2024.
The report also revealed that five Pakistani cities recorded pollution levels exceeding 200 microns in November.
The study analysed data from "more than 40,000 air quality monitoring stations across 8,954 locations in 138 countries, territories and regions," according to IQAir's air quality scientists.
In Pakistan, nearly seven in ten people suffered health problems due to smog, according to a separate report by international insights firm Ipsos.
In terms of PM2.5 exposure, Chad's pollution levels were 18 times higher than WHO safe limits while India's levels were 10 times above the WHO-recommended threshold. Despite an improvement in 2024, India still accounted for six of the world's nine most polluted cities.
The report named Byrnihat as the "most polluted metropolitan area of 2024", while New Delhi was ranked the world's most polluted capital, followed closely by N'Djamena in Chad.
Other highly polluted capitals included Dhaka, Bangladesh (3rd place), Kinshasa, DR Congo (4th place) and Islamabad, Pakistan (5th place).
Byrnihat, an industrial town on the border of Meghalaya and Assam, recorded an average PM2.5 level of 128.2 micrograms per cubic metre in 2024, which is more than 25 times the WHO recommended level of five micrograms.
Across India, PM2.5 concentrations averaged 50.6 micrograms per cubic metre, ten times above WHO safety levels. While South Asia continues to grapple with extreme pollution, Oceania was the cleanest region in 2024.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
2 hours ago
- Business Recorder
WHO maintains mpox alert amid West Africa surge
GENEVA: The World Health Organisation said Monday that the mpox virus epidemic remains an international health emergency with more than 37,000 confirmed cases reported since it erupted. WHO director general Tedros Adhanom Ghebreyesus announced the extension of the emergency following a meeting of international experts who noted progress in some countries but also highlighted a surge in west Africa and the spread of the virus outside Africa. The WHO said since the epidemic started in early 2024 in Democratic Republic of Congo, there have been more than 37,000 cases in 25 countries, including 125 deaths. Mpox: health dept for ensuring strict screening steps at Karachi airport DR Congo accounts for 60 percent of the confirmed cases and 40 percent of the deaths from the virus, that causes a rash and severe flu-like symptoms. Uganda and Burundi have been the next worst hit, followed by Sierra Leone, which the WHO said has seen a surge in cases this year. WHO first declared mpox an international emergency in August last year. The International Health Regulations emergency committee met last Thursday to discuss the epidemic. It decided that the epidemic remains an international emergency "based on the continuing rise in the number of cases, including a recent increase in West Africa, and likely ongoing undetected transmission in some countries beyond the African continent." It said some countries were still struggling to monitor the epidemic and with a lack of funding for treatment there was a need for "continued international support".
Business Recorder
3 days ago
- Business Recorder
Pakistan's vaccine independence: a national imperative
Pakistan stands at a critical crossroads in public health policy. With seven million births annually and a population growth rate of 2.55%, our nation faces an unprecedented challenge in vaccine security that demands immediate and decisive action. The looming withdrawal of GAVI support by 2031 presents not just a crisis, but an opportunity to transform Pakistan into a self-reliant pharmaceutical powerhouse. The stark reality we face The numbers paint a sobering picture of our current vulnerability. Pakistan's complete dependency on donated and discounted vaccine supplies, supported by GAVI, UNICEF, and WHO to the tune of PKR 26 billion annually, masks a deeper structural weakness. When GAVI's support ends in 2031, the financial burden will balloon to PKR 100 billion annually as nearly four times our current federal health budget of PKR 27 billion. This dependency is not merely financial; it represents a fundamental threat to national health security. This isn't just underdevelopment—it's a systematic surrender of national health autonomy. Today, Pakistan produces virtually no antigens for the Expanded Programme on Immunization (EPI) vaccines domestically. We lack essential seed banks, have minimal university-based vaccine development programs, and operate with regulatory guidelines that are inadequate for sophisticated vaccine manufacturing. Our clinical trial expertise remains severely limited, creating bottlenecks in bringing locally developed vaccines to market. The contrast with global pharmaceutical leaders is stark. While universities worldwide have been the birthplace of revolutionary vaccines-from the Hepatitis B vaccine developed at UC San Francisco to the Oxford-AstraZeneca Covid-19 vaccine-Pakistan's academic institutions remain largely disconnected from commercial vaccine production. Learning from global success stories International experience offers valuable lessons. India transformed itself into the 'pharmacy of the world' through strategic government support for generic manufacturing and robust regulatory frameworks. Singapore built a biomedical hub through integrated research, manufacturing, and regulatory excellence that attracted billions in global pharmaceutical investment. South Korea's government-industry partnerships created world-class biopharmaceutical capabilities. These success stories share common elements: sustained government commitment, strategic investment in infrastructure, regulatory excellence, and comprehensive talent development programs. Most importantly, they demonstrate that with the right approach, developing nations can achieve pharmaceutical self-sufficiency and even become global exporters. The Triple Helix solution The path forward requires unprecedented coordination between government, academia, and industry -what experts call the 'Triple Helix' approach. Each sector must play a distinct yet interconnected role in building national vaccine capacity. Government leadership is essential in creating policy frameworks that incentivize domestic production while providing funding for university research. Strategic assignments to national research institutions like the National Institute of Health, Centre of Excellence in Molecular Biology (CEMB), National Institute for Biotechnology and Genetic Engineering (NIBGE), International Centre for Chemical and Biological sciences (ICCBS), Karachi University, Department of Biotechnology, Dow University of Health Sciences (DUHS), etc., can accelerate vaccine development and establish crucial seed banks. Most critically, the government must develop a comprehensive national health security strategy that positions vaccine self-sufficiency as a matter of national defense. The regulatory transformation cannot be understated. Pakistan's Drug Regulatory Authority must achieve WHO Level 3 qualification and create 'regulatory sandboxes — collaborative environments where university researchers, industry partners, and regulatory experts jointly develop guidelines for the 13 critical EPI vaccine antigens. Fast-track approval pathways and clear regulatory roadmaps will accelerate the journey from laboratory research to commercial production. Formation of sandboxes by bringing together leaders of the University, Regulatory and Industry. Universities must step up as innovation engines. Institutions with BSL-III laboratories should lead development of live attenuated vaccines, while biotechnology departments focus on recombinant vaccine technologies. Specialized vaccine research centers, industry-relevant curricula, and technology transfer offices will bridge the gap between academic discovery and commercial application. State-of-the-art pilot manufacturing facilities will provide proof-of-concept capabilities essential for scaling innovations. Industry brings manufacturing excellence and market expertise to the equation. Private sector partners can transform academic research into GMP-compliant commercial production, establish robust supply chains for raw materials, and navigate complex regulatory approvals. Their distribution networks and market access capabilities will ensure that domestically produced vaccines reach every corner of Pakistan. Leading companies in Pakistan already in the field of Biopharmaceutical manufacturing must be involved in the development process. A realistic implementation roadmap Success requires a phased approach spanning six years. The foundation phase (Years 1-2) must establish policy frameworks and coordination mechanisms while launching capacity-building programmes. Infrastructure development (Years 2-4) involves scaling laboratory manufacturing capabilities, establishing vaccine testing facilities, and launching pilot production programs. The scale-up phase (Years 4-6) transitions to commercial production of EPI vaccines, regulatory approvals, and distribution network establishment. Finally, the optimization phase (Year 6+) expands manufacturing capabilities, develops advanced biologics production, and positions Pakistan as a regional pharmaceutical hub. Financial innovation will be crucial. Blended financing models combining public funding, private investment, and support from institutions like the Islamic Development Bank can mobilise the substantial capital required for drug substance manufacturing facilities. The initial investment may be significant, but the long-term savings and export potential far outweigh the costs. The economic and strategic imperative The benefits extend far beyond health security. A robust domestic vaccine industry could create over 5,000 jobs and reduce import dependency by 50 percent. More importantly, it would establish Pakistan as a regional pharmaceutical hub with significant export potential to neighboring countries and the broader Islamic world. The Covid-19 pandemic demonstrated the critical importance of pharmaceutical self-reliance. Nations with domestic production capabilities could respond rapidly to their populations' needs, while others waited months for external supplies. This lesson cannot be ignored as we face an uncertain global health landscape. The time for action is now Pakistan's demographic dividend — with 65 percent of the population under 30 — represents an unprecedented opportunity to build a knowledge-based pharmaceutical sector. However, this window will not remain open indefinitely. The GAVI deadline of 2031 provides a clear timeline for action, but preparation must begin immediately. The success of this transformation depends on political will, sustained investment, and most importantly, recognition that vaccine self-sufficiency is not a luxury but a national security imperative. Countries that fail to develop domestic pharmaceutical capabilities will remain perpetually vulnerable to supply disruptions, price volatility, and foreign policy pressures. A call to national action The establishment of National and Provincial Coordination Committees bringing together leaders from academia, industry, and regulatory agencies represents the essential first step. This must be followed by a comprehensive assessment of current capabilities, development of a detailed national vaccine strategy, and launch of pilot programmes for immediate impact. Pakistan has the intellectual capital, institutional foundation and market potential to achieve vaccine independence. What we need now is the collective will to transform this potential into reality. The health and prosperity of future generations depend on the decisions we make today. The choice is clear: remain dependent on the goodwill of international donors or invest in building a self-reliant pharmaceutical sector that serves not only Pakistan's needs but positions the nation as a leader in global health innovation. The Triple Helix approach offers a proven pathway to pharmaceutical independence-we must have the courage to take it. Copyright Business Recorder, 2025
Business Recorder
4 days ago
- Business Recorder
Safer, smarter healthcare services: Federal, Punjab Health ministries to launch joint initiatives
ISLAMABAD: The Federal Health Ministry and the Punjab Health department have decided to join hands for stronger, safer, and smarter healthcare services. The major development for national health collaboration came here on Thursday during a high-level meeting between Federal Minister for Health Mustafa Kamal and Punjab Minister for Primary and Secondary Healthcare Khawaja Imran Nazir. The meeting focused on strengthening coordination between the federal and provincial governments to address critical healthcare challenges and launch joint initiatives across key health areas. The meeting decided taking joint action against counterfeit medicines, coordinated efforts on polio eradication and dengue prevention and advancement of digital health systems and regulatory reform. The meeting was also attended by Special Secretary Health Syed Waqarul Hassan, Additional Secretary Health, Chief Information Officer of DRAP, Director General Health, and the President of the Pakistan Medical and Dental Council (PMDC),Dr Rizwan Taj. Kamal reiterated the federal government's resolve to address healthcare issues with urgency. He stated that under the direction of the prime minister, particular focus is being placed on eliminating polio and ensuring timely implementation of health programmes. 'The fight against polio continues with full zeal, until the virus is eliminated, our children remain at risk,' he emphasised. He shared plans for a new national strategy for polio eradication and urged parents to disregard negative propaganda and ensure their children are vaccinated. 'In Palestine, even during war, mothers call for vaccinators with whistles. Pakistani mothers must also play their part in protecting their children,' he said. Kamal highlighted steps being taken by DRAP to combat counterfeit medicines, including the rollout of a modern barcode system. This will enable every medicine to carry a unique code that patients can scan to verify authenticity and price. Additionally, export certifications such as GMP, CoPP, and NOCs are now being processed online via the Pakistan Single Window, and all regulatory submissions are handled through the new 'e-App' online platform. Provincial Minister Khawaja Imran Nazir reaffirmed Punjab's full support for the federal government's health agenda. 'Punjab has greater capacity and resources, and we are ready to share these to benefit all provinces. The health of our people must come before all else,' he stated. He also praised DRAP's initiatives under the leadership of Minister Kamal, particularly, those targeting counterfeit pharmaceuticals. The two ministers agreed on the importance of coordinated measures to prevent dengue outbreaks in Islamabad and Rawalpindi and committed to united efforts in disease prevention, vaccination campaigns, and health system strengthening. They stressed that collaboration between federal and provincial levels is crucial to achieving meaningful progress in the health sector. Copyright Business Recorder, 2025
